New: NCI-funded clinical trial search
Mednet Logo
CommunityPulmonology

Would you reserve dupilumab for postsurgical recurrence or offer it upfront for high-burden disease in a patient with allergic fungal rhinosinusitis?

Luong et al., PMID 42498125
1 Answer
Mednet MemberInvited Expert
Allergy & Immunology · University of Mississippi School of Medicine
Answered on

This is a practical, salient question that has (at least as of yet) no definitive answer. Given the typical morbidity of AFRS patients with significant polyp burden and the not infrequent need for systemic steroid bursts to manage extreme symptom recurrence, it is not unreasonable to consider starti...

Join for free or sign in to see the full answer